Drug Approval | November 02, 2023
NATCO Pharma announces successful completion of USFDA inspection
NATCO's Pharmacovigilance Department was inspected from October 30, 2023 to November 1, 2023
NATCO's Pharmacovigilance Department was inspected from October 30, 2023 to November 1, 2023
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
The European Commission approved the use of Carbopol as an additive for liquid and solid food supplements in the EU
2023 Nobel laureates discovered how pseudouridine could make mRNA suitable for vaccines
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
Additional premium services in RegXcellence will include access to BASF’s Product Carbon Footprint data and direct downloads of audit reports
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
New effective carrier systems for drug delivery in different dosage applications including oral, topical & parenteral
Subscribe To Our Newsletter & Stay Updated
